$CELZ Creates W on Chart as it gets Accumulated Ahead of Updates
CELZ DD As It Stands, this is now one of my Long Term plays that I have added to my portfolio:I like what I see here and am glad to have the shares I have. Targeting BILLIONS IN REVENUE FOLKS AND THE TECHNOLOGY IS REAL AND PROVEN. AMAZING!!!
WORTHY OF A MARKET CAP 50-100 MILLION TODAY THATS A PPS .104 - .208!
Fellow investors it looks to me like management has been busy getting their ducks in a row. Cleaning up notes and debt. Using restricted shares and the CEO himself adding a huge chunk. We see almost 30% shares held by insiders.
Are they preparing for something much larger here. I still believe A 2018 BUY OUT IS IN THE WORKS!!!
The "ED" rollout continues and the WORD IS GETTING OUT with Creative Medical Technology Holdings gave the Keynote Speaker at Gathering of Health Care Innovators.
The Company's Stem Cell Therapies to be Main Subject at Dr. James Veltmeyer's Congressional Health Care Symposium.
Finalized with 8K letting us know where everything stands O/S.
TOTAL O/S: 480,035,712
(Nothingness with billions in rev's targeted via multiple diverse procedures! 20-36 Billion "ED" alone 18 Billion "MS" alone.)
INSIDER OWNERSHIP: 29.9% (143,489,101 shares)
FLOAT: 336,546,611 SHARES (This is nothingness folks)
SC 13 d/a
CREATIVE MEDICAL HEALTH INC.
sHARES 68,511,217
PERCENT OF O/S : 14.3%
TIMOTHY WARBINGTON
sHARES 74,977,884
PERCENT OF O/S : 15.6%
TOTAL PERCENT: 29.9% OF O/S INSIDERS HOLD!!!
FORM 4's:
CREATIVE MEDICAL HEALTH INC.
Purchases: 4-11-2018 9.855,290 shares at a price .0138 totaling $136,003
TIMOTHY WARBINGTON
Purchases: 4-12-2018 9,855,290 shares at a price .0138 totaling $136,003
TOTAL PURCHASE DOLLAR VALUE: $272,006
8k - Issued 4-13-2018
RECAP's the over a month of transaction:
From March 2, 2018 through April 12, 2018, we issued an aggregate of 144,585,823 shares upon the conversions of outstanding notes and 92,023,304 shares upon the cashless exercise of outstanding warrants. These conversions were made pursuant to the exemption provided by Section 3(a)(9) of the Securities Act of 1933. As a result of these issuances, we have outstanding 480,035,712 shares of common stock as of April 12, 2018.
TOTAL O/S: 480,035,712 This number matches the O/S number used to calculate the insider percentages above
Creative Medical Technology Holdings to be Keynote Speaker at Gathering of Health Care InnovatorsPress Release | 04/12/2018
Creative Medical Technology Holdings to be Keynote Speaker at Gathering of Health Care Innovators
The Company's Stem Cell Therapies to be Main Subject at Dr. James Veltmeyer's Congressional Health Care Symposium
otcmarkets.com/stock/CELZ/news/Creative-Medical-Technology-Holdings-to-be-Keynote-Speaker-at-Gathering-of-Health-Care-Innovators?id=189012
Shareholder Update: Creative Medical Technology Holdings
CELZ: NEW UPDATED 03/26/18 DD PACKAGE~~A clinical-stage biotechnology company focused on Urology and Neurology using stem cell treatments. CLICK HERE TO VISIT THE CREATIVE MEDICAL TECHNOLOGY HOLDING, INC WEBSITE
ERECTILE DYSFUNCTION CLINICAL TRIALS
Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) announced today that debt to affiliate company Creative Medical Health, Inc. in the amount of $136,003.00 is being converted to restricted common shares of stock in Creative Medical Technology Holdings, Inc.
"As we certainly have confidence in the fundamentals of Creative Medical Technology Holdings, Inc., in our stem cell technology and in the experience and ability of our network of doctors, scientists and our executives we have determined that this is a prudent action to eliminate additional debt and to continue to build shareholder value.
And as a reminder, May 18-20 we'll be at the American Urological Association (AUA) conference at booth 5870 presenting our CaverstemTM erectile dysfunction technology. Our team is excited and ready to go!"
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.